Compare FFIN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIN | ERAS |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.0B |
| IPO Year | 1994 | 2021 |
| Metric | FFIN | ERAS |
|---|---|---|
| Price | $34.79 | $19.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $36.50 | $14.25 |
| AVG Volume (30 Days) | 896.0K | ★ 5.6M |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | 13.46 | ★ 36.23 |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.16 | N/A |
| Revenue Next Year | $6.61 | N/A |
| P/E Ratio | $69.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.12 | $1.33 |
| 52 Week High | $38.12 | $24.28 |
| Indicator | FFIN | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 59.92 |
| Support Level | $31.30 | $17.63 |
| Resistance Level | $35.77 | $24.28 |
| Average True Range (ATR) | 0.76 | 1.30 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 30.34 | 46.33 |
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.